HIGHLIGHTS
- who: Maarit Tarkiainen from the Childrenu2019s Hospital, Helsinki University Central Hospital, , HUS, Helsinki, Finland have published the research: Economic evaluation of infliximab, synthetic triple therapy and methotrexate in the treatment of newly diagnosed juvenile idiopathic arthritis, in the Journal: (JOURNAL)
- what: The authors used the data collected in the ACUTE-JIA study to assess short-term costs and cost-effectiveness of infliximab plus methotrexate compared with triple or monotherapy of DMARDs in an early aggressive treat-to-target approach. The authors demonstrated that during the first year of treatment of polyarticular JIA, IFX + MTX had . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.